Liver blood flow in chronic hemodialysis patients

Nephron

Volumn 73, Issue 3, 1996, Pages 396-402

  Leblanc, Martwe ^a   Roy, Louise F ^a   Villeneuve, Jean Pierre ^a   Malo, Bernard ^a   Pomier Layrargues, Gilles ^a   Legault, Louis ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Hemodialysis; Liver blood flow; Sorbitol

Indexed keywords

SORBITOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART OUTPUT; HEMODIALYSIS; HUMAN; LIVER BLOOD FLOW; LIVER CLEARANCE; MALE; PLASMA CLEARANCE; PRIORITY JOURNAL;

EID: 0029934010     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000189099     Document Type: Article

References (45)

1. Gibson TP: Renal disease and drug metabolism: An overview. Am J Kidney Dis 1986:8: 7-17.
2. Goldberg JP, Anderson RJ: Renal metabolism and excretion of drugs: in Scldin DW. Gicbisch G (eds): The Kidney: Physiology and Pathophysiology. New York. Raven Press. 1985. pp 2097-2110.
3. Rcidenberg MM: The biotransformation of drugs in renal failure. Am J Med 1977,62:482-485.
4. Simon P. Meyrier A, Brissot P: Uremia and the liver. H. Drugs and the liver in the uremic patient. Nephron 1981;29:7-13.
5. Leber HW. Schutterle G: Oxidative drug metabolism in liver microsomes from uremia rats. Kidney Int 1972;2:152-158.
6. Mabuchi H. Kanahasi H: Inhibition of hepatic glutathione-S-transferases by a major endogenous ligand substance present in urcmic scrum. Nephron 1988:49:281-283.
7. Valcntovic M. Backmann K: Effects of urea on hexobarbital and antipyrine disposition in rats. Pharmacology 1980:21:167-174.
8. Leber HW. Gleumes L. Schutterle G: Enzyme induction in the uremic liver. Kidney Int 1978; 13(supp1):S43-S48.
9. Wilkinson GR. Shand DG: A physiological approach to hcpaticdrugclearance. Clin Pharmacol Ther 1975:18:377-390.
10. Hiley CR. Yates MS, Robert PJ. Bloom AE: Alterations in liver blood flow during glycerol-induced acute renal failure in the rat. Nephron 1980;26:244-248.
11. Kishimoto T. Shakmoto W. Nakalani T. Ito T. Iwai K. Kin T, Abe Y: Cardiac output, renal blood flow, and hepatic blood flow in rats with glycerol-indueced acute renal failure. Nephron 1989:53:353-357.
12. Nakatani T, Kishimoto T, Kin T. Sujino T, Okayama T, Iwai Y, Maekawa M: Hepatic blood flow and drug metabolism in glycerol-rechallenged rats. Urol Res 1989;17:235-237.
13. Bowmer CJ. Yates MS. Emmcrson J: The effect of acute renal failure on the pharmacokinetics of indocyaninc green in the rat. Biochem Pharmacol 1982:31:2531-2538.
14. Awni WM. Luke DR. Opsahl JA. Halstenson CE. Matzkc GR: Hepatic blood flow (HBF) and oxidative metabolism (HOM) in hemodialysis patients. Clin Pharmacol Thcr 1988:43: 147.
15. Skak C, Keiding S: Methodological problems in the use of indocyanine green to estimate hepatic blood flow and ICG clearance in man. Liver 1987;7:155-162.
16. Burns E, Trigcr DR. Tucker GT. Bax NDS: Indocyaninc green eliminated in patients with liver disease and in normal subjects. Clin Sci 1991:80:155-160.
17. Bergmeyer HU. Gruber W. Guttman I: D-Sorbitol; in: Methods of Enzymatic Analysis. Weinheim. Verlag Chemie. 1975, pp 1323-1330.
18. Demassieux S, Corneille L, Lachance S, Carrière S: Determination of free and conjugated catecholamines and β.,-3.,4-dihydroxvphenylal-anine in plasma and urine: Evidence for a cate-chol-O-methyltransferasc inhibitor in uremia. Clin Chim Acta 1981;115:377-391.
19. Williams GA. Labovitz AJ: Doppler estimation of cardiac output: Principles and pitfalls. Echo cardiography 1987:4:355.
20. Scijalian AM. Stansky GP. Hobbs KEF: Measurement of liver blood: A review. HPB Surg 1991;4:171-186.
21. Lafortune M. Dauzat M. Pomier-Layrargues G. Gianfclicc D. Lepanto L. Breton G. Marleau D. Dagenais M. Lapointe R: Hepatic artery: The effect of a meal in healthy persons and transplant recipients. Radiology 1993:187: 391-394.
22. Keiding S: Hepatic clearance and liver blood flow, Hepatol 1987;4:393-398.
23. Lccvv CM, Mendenhall CL. Lcsko W. Howard MM: Estimation of hepatic blood flow with indocyanine green. J Clin Invest 1962:41: 1169-1179.
24. Keiding S: Galactose clearance measurements and liver blood flow. Gastroenterology 1988; 94:477-481.
25. Zeeh J. Lange H. Bosch J, Pohl S, Loesgen H. Eggers R. Navasa M. Chesta J. Bircher J: Steady-state extrarcnal sorbitol clearance as a measure of hepatic plasma flow. Gastroenterology 1988:95:749-759.
26. Grainger SL. Keeling PWN, Brown IMH. Marigold JH. Thompson RPH: Clearance and non-invasive determination of the hepatic extraction of indocyanine green in baboons and man. Clin Sci 1983:64:207-212.
27. Henderson JM. Millikan WJ, Hooks M, Noe B. Kutner MH. Warren WD: Increased galactose clearance after liver transplantation: A measure of increased blood flow through the dencr-vatcd liver? Hepatology 1989:10:288-291.
28. Kawasaki S. Sugivama Y. Iga T. Hanano B. Bcppu T, Sugiura M. Sanjo K. Idczuki Y: Hepatic clearance of antipyrine, indocyanine green and galactose in normal subjects and in patients with chronic liver diseases. Clin Pharmacol Ther 1988;44:217-224.
29. Zaramella MG. Vallini R. Tiribelli C: Estimation of the hepatic blood flow by galactose plasma clearance in patients with liverdisease. Liver 1985:5:129-133.
30. Zenilman ME. Flye MW: Galactose clearance and hepatic blood flow. Gastroenterology 1989:96:268.
31. Molino G, Cavanna A, Avagnina P. Ballare M, Torchio M: Hepatic clearance of /9-sorbitol: Non-invasive test for evaluating functional liver plasma flow. Dig Dis Sci 1987;32:753-758.
32. Molino G. Avergnina P. Ballare M. Torchio M. Niro AG, Aurucci PE, Grosso M. Fava C: Combined evaluation of total and functional liver plasma flows and intrahepatic shunting. Dig Dis Sci 1991:36:1189-1196.
33. Karrenberg R. Stobcr HD: The dangers of fruc-tose-sorbitol infusions. Anacsthesiol Reanim 1990;15:181-187.
34. Tcrao N. Shen DD: Reduced extraction of /.,-propranolol by perfused rat liver in the presence of uremic blood. J Pharmacol Exp Ther 1985:233:277-284.
35. Parfrcy PS. Harnett JD. Griffiths SM. Gault MH, Barré PA: Congestive heart failure in dialysis patients. Arch Intern Med 1988; 148:1519-1525.
36. Elias AN, Vaziri ND. Maksy M: Plasma norepinephrine. epinephrine and dopamine levels in end-stage renal disease: Effect of hemodialysis. Arch Intern Med 1985:145:1013-1015.
37. Kim KE. Oncsti G. DelGucrcio ET. Greco J. Fernandes M. Eidelson B. Swartz C: Sequential hemodynamic changes in end-stage renal disease and the ancphric state during volume expansion. Hypertension 1980:2:102-110.
38. Neff MS. Kim KE. Persoff M. Oncsti G. Swartz C: Hemodynamics of uremic anemia. Circulation 1971:43:876-883.
39. Metra M. Cannclla G. LaCanna G. Ciuaini T. Sandrini M. Gaggiotti M. Movilli E, Dcicas L: Improvement in exercise capacity after correction of anemia in patients with end-stage renal failure. Am J Cardiol 1991:68:1060-1066.
40. Tagawa H, Nagano M. Saito H. Umczu M, Yamakado M: Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: Proposal for a hematocrit most beneficial to hemodynamics. Clin Nephrol 1991:35:35-38.
41. Schohn D. Weidmann P. Jahn H. Bcrctta-Pic-coli C: Norepinephrine-related mechanism in hypertension accompanying renal failure. Kidney Int 1985:28:814-822.
42. Izzo JL. Santarose RP, Larrabce PS. Smith RJ. Kallav MC: Increased plasma norepinephrine and sympathetic nervous activity in essential hypertensive and uremic humans: Effects of clonidinc. J Cardiovasc Pharm 1987; 19(suppl 12):S225-S229.
43. Anderson CB. Codd JR. Graff RA. Grace MA, Harter HR. Newton WT: Cardiac failure and upper extremity arteriovenous dialysis fistula. Arch Intern Med 1976:3:292-297.
44. Converse RL, Jacobsen TN, Toto RD. Jost CMT, Conscntino F, Fouad-Tarazi F. Victor RG: Sympathetic ovcractivitv in patients with chronic renal failure. N Engl J Med 1992:327: 1912-1918.
45. Schlant RC, Sonnenblick EH: Normal physiology of the cardiovascular system; in Hurst JW (ed): The Heart, ed 6,1985, pp 1-37.